Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydroxychloroquine + dexamethasone
- Development stage
- Unknown
- Lead developer
- Yunfeng Cheng
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Hydroxychloroquine + dexamethasone is a combination therapeutic regimen being investigated for the treatment of antinuclear antibody (ANA)-positive primary immune thrombocytopenia (ITP). Hydroxychloroquine is an established antimalarial and immunomodulatory small molecule that inhibits lysosomal activity and Toll-like receptor (TLR) signaling, particularly TLR7 and TLR9. Dexamethasone is a potent synthetic glucocorticoid that provides broad immunosuppression by activating the glucocorticoid receptor. This specific combination is being evaluated in clinical trials led by researcher Yunfeng Cheng at Zhongshan Hospital, Fudan University, to determine if the addition of hydroxychloroquine to standard dexamethasone therapy improves platelet response rates and duration in adult ITP patients who test positive for ANA, a subpopulation often associated with refractory disease.
- Other names
- HCQ + DEXhydroxychloroquine plus dexamethasone
02
Targets
GR (Glucocorticoid receptor)TLR9 (Toll-like receptor 9)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on hydroxychloroquine + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydroxychloroquine + dexamethasone.